NCT01121588 2025-01-23Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)PfizerPhase 1 Terminated44 enrolled 22 charts 1 FDA
NCT01606878 2024-01-05Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaChildren's Oncology GroupPhase 1 Completed46 enrolled 24 charts